CLS · NYSE
| FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|
| Total Revenue | $12.39B | $9.65B | $7.96B | $7.25B |
| Cost of Revenue | $10.90B | $8.61B | $7.21B | $6.60B |
| Gross Profit | $1.49B | $1.03B | $754.10M | $649.70M |
| Research & Development | $118.20M | $78.00M | $60.90M | $46.30M |
| Selling, General & Administrative | $259.90M | $293.50M | $303.20M | $267.30M |
| Operating Income | $1.04B | $599.30M | $338.30M | $289.30M |
| Other Income / (Expense) | -$4.90M | -$15.00M | $46.60M | $1.50M |
| Income Before Taxes | $983.20M | $532.20M | $306.00M | $239.10M |
| Provision for Income Taxes | $150.70M | $104.20M | $61.60M | $59.00M |
| Net Income | $832.50M | $428.00M | $244.40M | $180.10M |
| Basic EPS | $7.22 | $3.62 | $2.03 | $1.46 |
| Diluted EPS | $7.16 | $3.61 | $2.03 | $1.46 |
| Basic Shares Outstanding | 115.30M | 118.10M | 120.10M | 123.50M |
| Diluted Shares Outstanding | 116.20M | 118.70M | 120.30M | 123.60M |
| Period | Consensus EPS | Low | High | Estimates | Revisions |
|---|---|---|---|---|---|
| Dec 2026 | $9.97 | $9.52 | $10.70 | 3 | ↑2 ↓0 |
| Dec 2027 | $15.96 | $12.65 | $19.28 | 3 | ↑2 ↓0 |